Gain Therapeutics, Inc. (GANX) Corporate Subsidiaries
Gain Therapeutics, Inc. (GANX) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: GANX
CIK: 1819411
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young AG
Auditor SinceSince 12/31/2020 12:00:00 AM
Lead Engagement PartnerFrederik Schmachtenberg
Audit LocationLugano, Switzerland
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-01 | 2026-10-01 | FORM 8-K | 0001104659-26-112624 | View SEC Doc Filr Page |
| 8-K | 2026-09-28 | 2026-09-22 | FORM 8-K | 0001104659-26-111391 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | 10-Q | 0001104659-26-094048 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001104659-26-094041 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | OWNERSHIP DOCUMENT | 0001104659-26-084439 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | OWNERSHIP DOCUMENT | 0001104659-26-084438 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | OWNERSHIP DOCUMENT | 0001104659-26-084437 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | OWNERSHIP DOCUMENT | 0001104659-26-084435 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | OWNERSHIP DOCUMENT | 0001104659-26-084434 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | OWNERSHIP DOCUMENT | 0001104659-26-084433 | View SEC Doc Filr Page |
| 8-K | 2026-07-16 | 2026-07-16 | FORM 8-K | 0001104659-26-084086 | View SEC Doc Filr Page |
| 8-K | 2026-06-29 | 2026-06-29 | FORM 8-K | 0001104659-26-078848 | View SEC Doc Filr Page |
| 8-K | 2026-06-25 | 2026-06-24 | FORM 8-K | 0001104659-26-077820 | View SEC Doc Filr Page |
| 8-K | 2026-05-26 | 2026-05-26 | FORM 8-K | 0001104659-26-066062 | View SEC Doc Filr Page |
| 10-Q | 2026-05-11 | 2026-03-31 | 10-Q | 0001104659-26-058649 | View SEC Doc Filr Page |
| 8-K | 2026-05-11 | 2026-05-11 | 8-K | 0001104659-26-058636 | View SEC Doc Filr Page |
| ARS | 2026-04-28 | 2025-12-31 | ARS | 0001104659-26-050437 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-28 | — | DEFA14A | 0001104659-26-050435 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-28 | 2026-06-24 | DEF 14A | 0001104659-26-050431 | View SEC Doc Filr Page |
| 4 | 2026-03-26 | 2026-03-24 | OWNERSHIP DOCUMENT | 0001104659-26-035403 | View SEC Doc Filr Page |
| 4 | 2026-03-26 | 2026-03-24 | OWNERSHIP DOCUMENT | 0001104659-26-035400 | View SEC Doc Filr Page |
| 10-K | 2026-03-26 | 2025-12-31 | 10-K | 0001104659-26-035188 | View SEC Doc Filr Page |
| 8-K | 2026-03-26 | 2026-03-26 | 8-K | 0001104659-26-035174 | View SEC Doc Filr Page |
| 8-K | 2026-03-18 | 2026-03-18 | FORM 8-K | 0001104659-26-029968 | View SEC Doc Filr Page |
| 8-K | 2026-02-03 | 2026-02-03 | FORM 8-K | 0001104659-26-009747 | View SEC Doc Filr Page |